Navigation Links
New drug shows potential for treatment-resistant leukemia
Date:4/11/2011

BOSTON (April 11) --A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

Appearing in the journal Cancer Cell, the study is the first published report showing that the drug, DCC-2036, fights chronic myeloid leukemia (CML) in a mouse model of the disease and is effective against human leukemia cells.

"These findings demonstrate that DCC-2036 is an excellent candidate for clinical development as a treatment for resistant CML. Not all drugs that work in a test tube will actually be effective in a living organism such as our mouse model," said Richard Van Etten, MD, PhD, Director of Tuft's Medical Center's Cancer Center and senior author of the study.

Other authors of the study are scientists with Deciphera Pharmaceuticals LLC of Lawrence, Kansas, and Emerald Biostructures of Bainbridge Island, WA.

DCC-2036 is a tyrosine kinase inhibitor (TKI), a class of drugs that block the action of an abnormal enzyme, BCR-ABL1, that sends chemical messenges that tell CML cells to grow. The development of TKI drugs such as imatinib (Gleevec) dramatically improved the prognosis for patients with CML, which strikes about 5,000 new patients each year in the United States. But about a third of patients will eventually relapse, principally because of mutations that render BCR-ABL1 resistant to the TKI. Such patients are left with few treatment options other than bone marrow transplantation.

The study showed that in human cells taken from treatment-resistant patients who had received the new drug, DCC-2036 tamped down the mutant enzyme that led to their relapse. The study also found that the drug killed malignant cells and prolonged survival in a mouse model of CML developed by Van Etten's team.

Deciphera Pharmaceuticals, LLC used crystal structures of BCR-ABL1 to custom-design the novel drug to inhibit the mutant enzyme that leads to treatment resistance in CML patients. "The study illustrates the power of designing drugs based upon structures of the target and initial testing of these drugs in mouse models before proceeding to the clinic. This type of targeted design is a paradigm for how cancer treatments will be developed in the 21st century," Van Etten said.


'/>"/>

Contact: Julie Jette
jjette@tuftsmedicalcenter.org
617-636-3265
Tufts Medical Center
Source:Eurekalert

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trials
2. Warning labels better than a fat tax, University of Alberta study shows
3. Unemployment Plays Role in Early Deaths, Research Shows
4. Research shows blood protein levels may predict risk of a cardiovascular event: Study
5. Long-term study shows that kidney transplants are faring better than previously reported
6. New drug shrinks cancer in animals, U-M study shows
7. Simple chemical cocktail shows first promise for limb re-growth in mammals
8. Elevated levels of sodium blunt response to stress, study shows
9. Study shows that modern surgery for scoliosis has good long-term outcomes
10. Minimally Invasive Heart-Valve Procedure Shows Promise: Study
11. PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: